Broadcast Date: November 28th, 2017
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
Chimeric antigen receptor T (CAR-T) cells are promising treatments for hematologic and solid malignancies. CAR-T cells can recognize and eliminate neoplastic cells expressing specific protein antigens. However, the current generation of CAR-T cells cannot distinguish between neoplastic and normal cells that may also be expressing the same antigen, thus potentially resulting in “on-target/off-tumor” toxicity. In this GEN webinar, we will review the RNAscope® in situ hybridization (ISH) method and show applications of the technology in the CAR-T cell and immuno-oncology fields. We will demonstrate how RNAscope ISH can be utilized to identify novel CAR-T cell targets and subsequently qualify monoclonal antibodies directed against those targets for immunohistochemistry. We will show how ISH can be used to predict CAR-T cell target organ toxicity in preclinical models. Finally, we will discuss optimal preparation of tissues, cell pellets, and cytospin slides for evaluation by ISH.
You Will Learn
- How RNAscope ISH technology can streamline your target identification and selection workflows
- The advantages of using ISH for immunotherapeutic target cell selection
- How ISH evaluation of target expression in normal tissues can be used to predict CAR-T cell induced toxicity
- Optimal tissue, cell pellet, and cytospin slide preparation for RNAscope ISH
James B. Rottman, D.V.M., Ph.D., D.A.C.V.P.
Senior Director of Translational Development,
Courtney Anderson, Ph.D.
Group Leader Applications,
Advanced Cell Diagnostics